Kane Biotech Inc Capital Reinvestment Ratio

Latest as of June 2023: 0.15x

Kane Biotech Inc capital reinvestment ratio. Kane Biotech Inc (KNE) has a Capital Reinvestment Ratio of 0.15x as of June 2023, meaning it reinvests 0% of its operating cash flow (CA$382.38K) in capital expenditures (CA$58.65K). Check KNE cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.15x

Capex / Operating Cash Flow

Operating Cash Flow

CA$382.38K

CAD

Capital Expenditures

CA$58.65K

CAD

Data as of

Jun 2023

Most recent filing

Kane Biotech Inc Capital Reinvestment Ratio by Year (None–None)

Kane Biotech Inc capital reinvestment ratio by year from None to None. For the full cash flow conversion analysis, see Kane Biotech Inc cash conversion from operations.

Year	Reinvestment Ratio	Operating CF (CAD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow